Beta Bionics (BBNX) EBIT Margin (2024 - 2026)

Beta Bionics has disclosed EBIT Margin across 3 years of filings, most recently posting 87.86% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 87.86%, up 1783.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 70.13% (up 783.0% YoY), and the FY2025 annual result was 71.5%, down 202.0% from the prior year.
• EBIT Margin came in at 87.86% for Q1 2026 at Beta Bionics, down from 50.2% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 50.2% in Q4 2025 to a low of 105.69% in Q1 2025.
• The 3-year median for EBIT Margin is 73.09% (2024), against an average of 74.74%.
• Across the five-year window, EBIT Margin slumped 3259 bps in 2025 and surged 1783 bps in 2026, its largest moves.
• Beta Bionics' EBIT Margin stood at 63.78% in 2024, then climbed by 21 bps to 50.2% in 2025, then tumbled by 75 bps to 87.86% in 2026.
• The last three EBIT Margin figures came in at 87.86% (Q1 2026), 50.2% (Q4 2025), and 62.54% (Q3 2025), per Business Quant data.